Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARDELYX, INC.ARDX · Entity 4972 | Chief Financial Officer | August 21, 2025 | August 25, 2025 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | EVP, CFO & Treasurer | January 20, 2017 | January 24, 2017 |
| ZEVRA THERAPEUTICS, INC.ZVRA · Entity 5212 | CFO | March 18, 2026 | March 19, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARDELYX, INC.
Report date August 21, 2025 · Filed August 25, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 409,052 |
Reported balance
After 2025-08-21 transaction · row 1
1 source rowRow 1 · 2025-08-21 · Sale · Disposed 7,037 · Balance 409,052 F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes.
Karyopharm Therapeutics Inc.
Report date January 20, 2017 · Filed January 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $10.39 · Expires 2027-01-19 | Direct | 100,000 |
Reported balance
After 2017-01-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-01-20 · Grant · Acquired 100,000 · Balance 100,000 F1: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter.
ZEVRA THERAPEUTICS, INC.
Report date March 18, 2026 · Filed March 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.55 · Expires 2036-03-17 | Direct | 300,000 |
Reported balance
After 2026-03-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-03-18 · Grant · Acquired 300,000 · Balance 300,000 F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, March 18, 2026. F2: Grant to the Reporting Person of a stock option under the Issuer's 2023 Employment Inducement Award Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. All shares underlying the option will vest in full and become exercisable immediately prior to a change of control of the Issuer. Vesting of the option will be accelerated by 12 months if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, March 18, 2026.
F2: Grant to the Reporting Person of a stock option under the Issuer's 2023 Employment Inducement Award Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. All shares underlying the option will vest in full and become exercisable immediately prior to a change of control of the Issuer. Vesting of the option will be accelerated by 12 months if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2026 Filed Mar 19, 2026 16:15 UTC | ZEVRA THERAPEUTICS, INC. ZVRA · Entity 5212 | GrantStock Option (right to buy) · Derivative | 300,000 | $0.00 Strike: $9.55 | $0.00 |
DisclosureSEC source: 0001466562-26-000007 · wk-form4_1773951351.xml · derivative · entry 1 Renz Justin A · CIK 0001466562 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2036-03-17 F1 · derivative.exercise_price: The exercise price is equal to the closing price of the Issuer's common stock on the Nasdaq Global Select Market on the date of grant, March 18, 2026. F2 · derivative.exercise_date: Grant to the Reporting Person of a stock option under the Issuer's 2023 Employment Inducement Award Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. All shares underlying the option will vest in full and become exercisable immediately prior to a change of control of the Issuer. Vesting of the option will be accelerated by 12 months if the Reporting Person is terminated without cause or resigns for good reason. The option expires ten years after the date of grant. Read SEC document |
| August 21, 2025 Filed Aug 25, 2025 21:12 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 7,037 | $5.93 | $41,741.37 |
DisclosureSEC source: 0001628280-25-041137 · wk-form4_1756170732.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 409,052 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| May 20, 2025 Filed May 22, 2025 21:53 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 7,218 | $4.08 | $29,459.55 |
DisclosureSEC source: 0001628280-25-027431 · wk-form4_1747965215.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 416,089 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 659 shares under the Ardelyx Employee Stock Purchase Plan in February 2025. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 18:01 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 205,019 | $0.00 Strike: $5.18 | $0.00 |
DisclosureSEC source: 0001628280-25-008798 · wk-form4_1740697262.xml · derivative · entry 2 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 205,019 Underlying: Common Stock · 205,019 shares Expires 2035-02-25 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of February 25, 2025, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| February 25, 2025 Filed Feb 27, 2025 18:01 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 136,680 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-008798 · wk-form4_1740697262.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 422,648 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| February 20, 2025 Filed Feb 21, 2025 18:55 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 5,171 | $5.62 | $29,076.53 |
DisclosureSEC source: 0001628280-25-007232 · wk-form4_1740182111.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 285,968 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: Transaction was executed in multiple trades in prices ranging from $5.601611 to $5.625428, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| November 20, 2024 Filed Nov 22, 2024 18:33 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 5,260 | $4.79 | $25,219.07 |
DisclosureSEC source: 0001628280-24-049053 · wk-form4_1732318388.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 291,139 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,142 shares under the Ardelyx Employee Stock Purchase Plan in August 2024. Read SEC document |
| August 20, 2024 Filed Aug 22, 2024 18:25 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 5,289 | $5.86 | $30,995.13 |
DisclosureSEC source: 0001628280-24-038291 · wk-form4_1724365500.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 295,257 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| May 21, 2024 Filed May 23, 2024 16:15 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 5,167 | $7.81 | $40,359.44 |
DisclosureSEC source: 0001628280-24-024944 · wk-form4_1716495332.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 300,546 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 878 shares under the Ardelyx Employee Stock Purchase Plan in February 2024. Read SEC document |
| February 20, 2024 Filed Feb 22, 2024 17:01 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 5,341 | $8.75 | $46,713.99 |
DisclosureSEC source: 0001610717-24-000087 · form4.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 304,835 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 16:36 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 164,000 | $0.00 Strike: $8.78 | $0.00 |
DisclosureSEC source: 0001628280-24-001684 · wk-form4_1705613767.xml · derivative · entry 2 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 164,000 Underlying: Common Stock · 164,000 shares Expires 2034-01-16 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 16, 2024, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 16, 2024 Filed Jan 18, 2024 16:36 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 127,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-001684 · wk-form4_1705613767.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 310,176 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 17:44 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001628280-23-042828 · wk-form4_1703803478.xml · derivative · entry 3 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,000 Underlying: Common Stock · 75,000 shares Expires 2032-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2023. F3 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 17:44 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 225,000 | $6.36 | $1,430,122.50 |
DisclosureSEC source: 0001628280-23-042828 · wk-form4_1703803478.xml · nonDerivative · entry 2 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 182,426 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $6.28 to $6.45, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| December 26, 2023 Filed Dec 28, 2023 17:44 UTC | ARDELYX, INC. ARDX · Entity 4972 | Exercise / conversionCommon Stock | 75,000 | $0.99 | $74,250.00 |
DisclosureSEC source: 0001628280-23-042828 · wk-form4_1703803478.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 407,426 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on September 12, 2023. Read SEC document |
| November 20, 2023 Filed Nov 22, 2023 17:20 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 2,873 | $4.36 | $12,532.60 |
DisclosureSEC source: 0001628280-23-039902 · wk-form4_1700691607.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 332,426 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,450 shares under the Ardelyx Employee Stock Purchase Plan in August 2023. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 16:42 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 2,884 | $3.55 | $10,243.39 |
DisclosureSEC source: 0001628280-23-030404 · wk-form4_1692823323.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 333,849 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $3.5135 to $3.551843, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 23, 2023 Filed May 25, 2023 08:53 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 2,873 | $3.65 | $10,495.64 |
DisclosureSEC source: 0001104659-23-064390 · tm2316962-4_4seq1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 336,733 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan in February 2023. Read SEC document |
| February 21, 2023 Filed Feb 24, 2023 17:37 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 3,439 | $3.00 | $10,320.44 |
DisclosureSEC source: 0001567619-23-003769 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 336,606 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 16:25 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 351,000 | $0.00 Strike: $2.73 | $0.00 |
DisclosureSEC source: 0001567619-23-000645 · doc1.xml · derivative · entry 2 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 351,000 Underlying: Common Stock · 351,000 shares Expires 2033-01-05 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2023, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 05, 2023 Filed Jan 6, 2023 16:25 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 78,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-23-000645 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 340,045 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 16:14 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 1,443 | $1.95 | $2,812.84 |
DisclosureSEC source: 0001567619-22-020846 · doc1.xml · nonDerivative · entry 2 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,045 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| November 22, 2022 Filed Nov 23, 2022 16:14 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 61 | $1.94 | $118.43 |
DisclosureSEC source: 0001567619-22-020846 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,488 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| August 31, 2022 Filed Sep 1, 2022 19:04 UTC | ARDELYX, INC. ARDX · Entity 4972 | PurchaseCommon Stock | 3,000 | $0.62 | $1,856.40 |
DisclosureSEC source: 0001567619-22-016958 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,549 F1 · balance_after: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan on August 31, 2022. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 17:42 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 12 | $0.98 | $11.76 |
DisclosureSEC source: 0001567619-22-016641 · doc1.xml · nonDerivative · entry 3 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,549 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 17:42 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 6 | $0.98 | $5.88 |
DisclosureSEC source: 0001567619-22-016641 · doc1.xml · nonDerivative · entry 2 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,561 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| August 22, 2022 Filed Aug 24, 2022 17:42 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 1,480 | $0.98 | $1,455.88 |
DisclosureSEC source: 0001567619-22-016641 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 260,567 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 20:03 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 1,518 | $0.64 | $964.84 |
DisclosureSEC source: 0001567619-22-012557 · doc1.xml · nonDerivative · entry 2 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 262,047 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| June 06, 2022 Filed Jun 8, 2022 20:03 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 71,794 | $0.65 | $46,730.71 |
DisclosureSEC source: 0001567619-22-012557 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,565 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| May 20, 2022 Filed May 23, 2022 16:36 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 1,528 | $0.67 | $1,025.90 |
DisclosureSEC source: 0001567619-22-011524 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,359 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan on February 28, 2022. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 16:58 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 1,800 | $0.67 | $1,206.00 |
DisclosureSEC source: 0001567619-22-005665 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 333,887 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| January 06, 2022 Filed Jan 12, 2022 19:48 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 196,000 | $0.00 Strike: $0.99 | $0.00 |
DisclosureSEC source: 0001567619-22-001140 · doc1.xml · derivative · entry 2 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 196,000 Underlying: Common Stock · 196,000 shares Expires 2032-01-06 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 6, 2022, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 06, 2022 Filed Jan 12, 2022 19:48 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 42,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-22-001140 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 335,687 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| November 22, 2021 Filed Nov 24, 2021 16:07 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 643 | $0.99 | $637.79 |
DisclosureSEC source: 0001567619-21-021163 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,687 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| October 08, 2021 Filed Oct 29, 2021 19:55 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-019029 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 294,330 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Reflects the adjusted total which includes the purchase of 1,283 shares under the Ardelyx Employee Stock Purchase Plan on February 28, 2021. F3 · balance_after: Reflects the adjusted total which includes the purchase of 3,000 shares under the Ardelyx Employee Stock Purchase Plan on August 31, 2021. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 18:07 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 631 | $1.32 | $832.92 |
DisclosureSEC source: 0001567619-21-016285 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,047 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| May 20, 2021 Filed May 21, 2021 16:48 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 612 | $7.09 | $4,337.73 |
DisclosureSEC source: 0001567619-21-010923 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,678 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 16:37 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 608 | $6.88 | $4,184.56 |
DisclosureSEC source: 0001567619-21-004769 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,290 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 19:14 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 146,755 | $0.00 Strike: $6.35 | $0.00 |
DisclosureSEC source: 0001567619-21-000768 · doc1.xml · derivative · entry 2 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 146,755 Underlying: Common Stock · 146,755 shares Expires 2031-01-05 F2 · derivative.exercise_date: The option becomes exercisable as it vests and the shares subject to the option vest in 48 successive, equal monthly installments on each monthly anniversary of January 5, 2021, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| January 05, 2021 Filed Jan 7, 2021 19:14 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 32,612 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-21-000768 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,898 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) shares of Common Stock for each one (1) RSU upon the vesting thereof. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 18:32 UTC | ARDELYX, INC. ARDX · Entity 4972 | SaleCommon Stock | 3,714 | $5.49 | $20,372.78 |
DisclosureSEC source: 0001567619-20-016848 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,286 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the initial grant of the restricted stock units ("RSUs") awards, the shares were sold upon the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $5.30 to $5.86, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:15 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantStock Option (Right to Buy) · Derivative | 195,017 | $0.00 Strike: $7.35 | $0.00 |
DisclosureSEC source: 0001567619-20-011933 · doc1.xml · derivative · entry 2 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 195,017 Underlying: Common Stock · 195,017 shares Expires 2030-06-08 F3 · derivative.exercise_date: The shares subject to the option vest according to the following schedule: Twenty-five percent (25%) of the shares subject to the option vest on the first anniversary measured from June 8, 2020, and the remaining shares subject to the option vest in 36 successive, equal monthly installments thereafter, subject to the Reporting Person's continued employment or service relationship with the Issuer on each such vesting date. Read SEC document |
| June 08, 2020 Filed Jun 9, 2020 20:15 UTC | ARDELYX, INC. ARDX · Entity 4972 | GrantCommon Stock | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-011933 · doc1.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 F1 · shares: Restricted stock units ("RSUs"). The Reporting Person is entitled to receive one (1) share of Common Stock for each one (1) RSU upon the vesting thereof. F2 · balance_after: Includes 10,000 RSUs. Read SEC document |
| January 20, 2017 Filed Jan 24, 2017 17:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 100,000 | $0.00 Strike: $10.39 | $0.00 |
DisclosureSEC source: 0001209191-17-005325 · doc4.xml · derivative · entry 1 Renz Justin A · CIK 0001466562 · EVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2027-01-19 F1 · derivative.exercise_date: This option was granted on January 20, 2017. The shares underlying this option vest as to 25% of the shares on January 20, 2018, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| November 09, 2016 Filed Nov 14, 2016 17:49 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 4,342 | $8.19 | $35,544.48 |
DisclosureSEC source: 0001209191-16-149852 · doc4.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · EVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,173 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. F2 · price: The sale price of the reporting person's shares represents the weighted average price of all shares sold by a broker on November 8, 2016 and November 9, 2016 on behalf of a group of employees of Karyopharm Therapeutics Inc. to satisfy the payment of withholding tax liability of such employees. Read SEC document |
| November 05, 2016 Filed Nov 8, 2016 16:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-148845 · doc4.xml · derivative · entry 2 Renz Justin A · CIK 0001466562 · EVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F3 · derivative.exercise_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016, and the remaining 50% of the restricted stock units will vest on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: On November 5, 2015, the reporting person was granted 30,000 restricted stock units. 50% of the restricted stock units vested on November 5, 2016, and the remaining 50% of the restricted stock units will vest on November 5, 2017. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| November 05, 2016 Filed Nov 8, 2016 16:11 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 15,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-148845 · doc4.xml · nonDerivative · entry 1 Renz Justin A · CIK 0001466562 · EVP, CFO & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,515 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Karyopharm Therapeutics Inc. common stock. F2 · balance_after: Includes 3,515 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.